Chronic kidney disease (CKD) affects approximately 10% of the global population, with hypertension and diabetes mellitus being the two leading causes. The renin-angiotensin-aldosterone system (RAAS) plays a central role in the progression of kidney damage in these conditions. Angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) are first-line therapies for slowing CKD progression and reducing cardiovascular risk. This article provides an authoritative, evidence-based review of their effectiveness, mechanisms, clinical evidence, limitations, and practical considerations for nephroprotection.

The Renin-Angiotensin-Aldosterone System and Kidney Injury

To understand why ACE inhibitors and ARBs protect the kidneys, one must first grasp the role of the RAAS in renal pathophysiology. In response to low blood pressure, reduced sodium delivery to the macula densa, or sympathetic stimulation, the kidneys release renin. Renin cleaves angiotensinogen to angiotensin I, which is then converted to angiotensin II by ACE. Angiotensin II is a potent vasoconstrictor that also stimulates aldosterone secretion, leading to sodium and water retention. Within the kidneys, angiotensin II constricts efferent arterioles more than afferent arterioles, thereby increasing intraglomerular pressure. This hemodynamic effect, while initially preserving glomerular filtration rate (GFR), eventually causes glomerular hypertension, hyperfiltration, and progressive scarring – a process known as glomerulosclerosis. Additionally, angiotensin II promotes inflammation, fibrosis, and oxidative stress within the renal parenchyma.

Mechanisms of ACE Inhibitors

ACE inhibitors, such as lisinopril, enalapril, ramipril, and perindopril, block the conversion of angiotensin I to angiotensin II. By reducing circulating and tissue angiotensin II levels, they cause vasodilation, decreased aldosterone release, and reduced sodium reabsorption. The key nephroprotective effect stems from preferential dilation of efferent arterioles, which lowers intraglomerular pressure. ACE inhibitors also reduce proteinuria by modifying the glomerular basement membrane's permselectivity and decreasing the production of pro-fibrotic cytokines such as transforming growth factor-beta (TGF-β). An additional benefit is the accumulation of bradykinin, a vasodilator that further lowers blood pressure but also contributes to the common side effect of cough.

Mechanisms of Angiotensin Receptor Blockers (ARBs)

ARBs, including losartan, valsartan, irbesartan, candesartan, and telmisartan, act at the receptor level by selectively blocking the angiotensin II type 1 (AT1) receptor. This prevents angiotensin II from exerting its vasoconstrictive, pro-inflammatory, and pro-fibrotic effects, regardless of whether the angiotensin II is generated via ACE-dependent or alternative pathways (e.g., chymase). Because AT1 blockade is more complete than ACE inhibition, ARBs often produce more predictable suppression of aldosterone release and greater reductions in proteinuria. Furthermore, unopposed stimulation of the AT2 receptor (which is not blocked) may provide additional vasodilatory and anti-proliferative benefits. ARBs do not affect bradykinin metabolism, which explains their lower incidence of cough and angioedema compared to ACE inhibitors.

Clinical Evidence for Nephroprotection

Decades of randomized controlled trials (RCTs) and meta-analyses have established the efficacy of RAAS blockade in slowing CKD progression. The landmark Collaborative Study Group trial (1993) demonstrated that captopril reduced the risk of doubling serum creatinine or progression to end-stage renal disease (ESRD) by 48% in patients with type 1 diabetes and proteinuria. Subsequent studies such as the RENAAL trial (losartan in type 2 diabetes) and the IDNT trial (irbesartan in type 2 diabetes) showed similar benefits, with ARBs reducing the composite endpoint of doubling creatinine, ESRD, or death by 20–30% compared to placebo or conventional antihypertensives. In non-diabetic CKD, the AASK trial in African-Americans and the REIN trial in proteinuric patients confirmed that ACE inhibitors slow GFR decline independent of blood pressure lowering.

Key Research Findings at a Glance

  • Proteinuria reduction: Both drug classes reduce urine protein excretion by 30–50% in the first 6–12 months, with the magnitude of reduction correlating with slower CKD progression.
  • Renal survival: In patients with baseline proteinuria >1 g/day, ACE inhibitors reduce the risk of ESRD by approximately 40% over 3–5 years.
  • Blood pressure-independent effects: Meta-analyses confirm that the renoprotective benefit exceeds what can be attributed to blood pressure lowering alone, especially in proteinuric patients.
  • Combination therapy: The combination of an ACE inhibitor and an ARB may further reduce proteinuria but does not improve renal outcomes and increases the risk of hyperkalemia and acute kidney injury; thus, dual blockade is no longer recommended.
  • Diabetic nephropathy: ARBs are the first-line agents for type 2 diabetes with albuminuria, while ACE inhibitors are first-line for type 1 diabetes with albuminuria.

The Role of Proteinuria as a Therapeutic Target

Proteinuria is not merely a marker of kidney damage but also a direct contributor to tubulointerstitial fibrosis. The filtered proteins, including albumin and immunoglobulins, trigger an inflammatory cascade in proximal tubular cells, leading to cytokine release, complement activation, and extracellular matrix deposition. Reducing proteinuria is therefore a surrogate endpoint for kidney protection. ACE inhibitors and ARBs are the most potent antiproteinuric agents available, and their dose-response relationship for this effect is often independent of blood pressure. Clinical guidelines recommend titrating the dose of these medications to achieve maximal proteinuria reduction (e.g., to <300 mg/g creatinine), even if blood pressure is well controlled. This "renin-angiotensin system blockade up-titration" strategy is supported by studies such as the ROADMAP trial and the IRMA-2 trial.

Specific Patient Populations

Hypertensive CKD Without Diabetes

In patients with hypertension and CKD (stage 1–3), ACE inhibitors or ARBs are recommended as first-line antihypertensive therapy, particularly when proteinuria is present. The ALLHAT trial, while showing no difference in major cardiovascular events between lisinopril, amlodipine, and chlorthalidone, confirmed that lisinopril reduced the risk of decline in GFR in African-American patients only when proteinuria was present. More recent studies emphasize that achieving blood pressure targets (typically <130/80 mmHg in CKD) with an ACE inhibitor or ARB provides superior kidney protection compared to other agents.

Diabetic Kidney Disease

For patients with type 1 diabetes and any degree of albuminuria, ACE inhibitors are the cornerstone of therapy, even in normotensive individuals. In type 2 diabetes, ARBs are preferred based on trial evidence, but the choice often depends on tolerability and cost. The ASCEND trial and ALTITUDE trial raised concerns about dual RAAS blockade (ACE inhibitor plus ARB plus direct renin inhibitor) increasing adverse events without added renal benefit. Current guidelines (KDIGO 2022, ADA 2024) recommend an ACE inhibitor or ARB for patients with diabetes and urine albumin-to-creatinine ratio (UACR) ≥30 mg/g.

Older Adults

Elderly patients with CKD are at higher risk of hyperkalemia and hypotension with RAAS blockade. However, the benefits of slowing CKD progression remain significant. A careful "start low, go slow" approach, with monitoring of serum potassium and creatinine within 1–2 weeks of initiation or dose adjustment, is essential. The STOP-ACEi trial (2022) suggested that discontinuing ACE inhibitors or ARBs in advanced CKD (eGFR <20 mL/min) did not improve physical function but did increase albuminuria; thus, continuation is generally recommended unless hyperkalemia or symptomatic hypotension develops.

Limitations, Side Effects, and Monitoring

Despite their efficacy, ACE inhibitors and ARBs are not without risks. The most common adverse effects include:

  • Hyperkalemia: Especially in patients with CKD stage 3–5, diabetes, or concomitant use of potassium-sparing diuretics or NSAIDs. Monitoring serum potassium at baseline and after dose changes is mandatory.
  • Acute kidney injury (AKI): Particularly in patients with volume depletion, bilateral renal artery stenosis, or severe heart failure. Transient rise in serum creatinine of up to 30% is acceptable and stabilizes over time; a larger increase warrants investigation for underlying causes.
  • Hypotension: Dose-dependent, especially when combined with diuretics. Using the lowest effective starting dose and titrating slowly reduces risk.
  • Cough (ACE inhibitors): A dry, non-productive cough occurs in 5–20% of patients; switching to an ARB resolves the cough in most cases.
  • Angioedema: Rare but potentially life-threatening; contraindicates future use of any ACE inhibitor and requires caution with ARBs.

Regular monitoring should include serum creatinine, eGFR, and potassium levels 1–2 weeks after initiation or dose adjustment, then every 3–6 months thereafter. Urine protein or albumin should be rechecked every 3–6 months to assess therapeutic response.

Combination Therapy: The Debate

Early observational studies and small RCTs suggested that combining an ACE inhibitor with an ARB produced additive reductions in proteinuria. This led to widespread off-label use. However, the ONTARGET trial (2008) compared ramipril, telmisartan, and their combination in high-risk patients. The combination group had more hypotension, syncope, and hyperkalemia, with no reduction in the primary composite renal endpoint. Subsequent studies, including the VA NEPHRON-D trial (2013), confirmed that dual blockade increased the risk of AKI and hyperkalemia without slowing CKD progression or reducing ESRD. Consequently, current KDIGO and ADA guidelines recommend against the routine use of ACE inhibitor + ARB combination therapy. A direct renin inhibitor (aliskiren) should also not be added to either drug class.

Guidelines and Clinical Practice Recommendations

Major international guidelines consistently endorse ACE inhibitors or ARBs as first-line therapy for CKD with albuminuria (UACR ≥30 mg/g) and for hypertension in CKD. Key recommendations include:

  • KDIGO 2022: Initiate an ACE inhibitor or ARB in patients with UACR 30–300 mg/g (A2 stage) and strongly recommend for UACR >300 mg/g (A3 stage). Target blood pressure <130/80 mmHg in most patients with CKD.
  • ADA 2024: For patients with diabetes and hypertension, use an ACE inhibitor or ARB if the UACR is 30–299 mg/g (moderately increased) and strongly recommend if UACR ≥300 mg/g.
  • ESC/ESH 2023: In hypertensive patients with CKD (eGFR <60 mL/min or proteinuria), an ACE inhibitor or ARB should be part of the treatment regimen.
  • KDOQI 2021: Dosing should be titrated to the maximum tolerated dose to achieve maximal antiproteinuric effect, provided serum potassium remains <5.5 mEq/L and eGFR decline does not exceed 30% in the first 3 months.

For further reading, refer to KDIGO 2022 CKD Guidelines and ADA Standards of Care 2024.

Emerging Therapies and Future Directions

While ACE inhibitors and ARBs remain foundational, newer agents targeting the RAAS at different points are being investigated. Aldosterone antagonists (e.g., spironolactone, eplerenone) show additive antiproteinuric effects when added to ACE inhibitors or ARBs, but the risk of hyperkalemia limits their use. The non-steroidal mineralocorticoid receptor antagonist finerenone demonstrated positive renal outcomes in the FIDELIO-DKD and FIGARO-DKD trials, leading to FDA approval for diabetic kidney disease. Sodium-glucose cotransporter-2 (SGLT2) inhibitors (empagliflozin, dapagliflozin, canagliflozin) also reduce proteinuria and slow GFR decline, and they can be used safely alongside ACE inhibitors or ARBs. The combination of an ACE inhibitor/ARB with an SGLT2 inhibitor and possibly finerenone is now considered a new standard of care for many patients with CKD and diabetes.

Practical Considerations for Clinicians

When initiating RAAS blockade, clinicians should consider the following:

  • Check baseline renal function, potassium, and UACR or urine protein-to-creatinine ratio (UPCR).
  • Start with a low dose (e.g., lisinopril 2.5–5 mg daily, losartan 25 mg daily) and titrate every 2–4 weeks based on blood pressure and laboratory values.
  • In patients with advanced CKD (eGFR <30 mL/min), exercise caution and consider nephrology consultation.
  • Advise patients to avoid NSAIDs, maintain hydration, and report symptoms of hypotension or hyperkalemia (e.g., palpitations, muscle weakness).
  • Re-assess UACR or UPCR 3 months after achieving the target dose; if proteinuria persists, consider adding an SGLT2 inhibitor (if eligible) or a non-steroidal MR antagonist (if eGFR >25 mL/min and potassium is normal).

Conclusion

ACE inhibitors and ARBs are among the most effective medications for preventing kidney damage in patients with hypertension, diabetes, or proteinuric CKD. Their ability to reduce intraglomerular pressure, lower albuminuria, and slow the decline in renal function has been proven in large-scale randomized trials spanning decades. When used appropriately with careful monitoring of potassium and renal function, they provide a substantial long-term benefit in delaying the onset of ESRD and reducing cardiovascular risk. However, the era of combination ACE inhibitor plus ARB therapy has passed due to safety concerns; modern strategies involve optimizing a single RAAS blocker to the maximum tolerated dose and integrating newer agents like SGLT2 inhibitors and finerenone for additional protection. Clinicians must remain vigilant in patient selection, dose titration, and longitudinal monitoring to harness the full nephroprotective potential of these well-established drugs.